[
  {
    "ts": null,
    "headline": "Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio",
    "summary": "Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in aggregate represent $1.4 trillion of value creation. The round includes participation from NFX, BOLD Capital Partners, Base4 Capital, Ke",
    "url": "https://finnhub.io/api/news?id=df263149909fa980125d1aa24912b432ea4fad64c75c94255f0acc9ae8857e5e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752006000,
      "headline": "Centivax Raises Oversubscribed $45 Million Series A Led by Future Ventures to Advance Universal Flu Vaccine into Clinic and Expand Universal Immunity Portfolio",
      "id": 135825078,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Centivax, Inc., a biotechnology company engineering vaccines and therapies for durable, universal protection against highly diverse targets, today announced the close of an oversubscribed $45 million Series A financing. The round was led by Steve Jurvetson of Future Ventures, an early backer of Tesla, SpaceX, Prellis Biologics, Cambrian Bio, and others which in aggregate represent $1.4 trillion of value creation. The round includes participation from NFX, BOLD Capital Partners, Base4 Capital, Ke",
      "url": "https://finnhub.io/api/news?id=df263149909fa980125d1aa24912b432ea4fad64c75c94255f0acc9ae8857e5e"
    }
  },
  {
    "ts": null,
    "headline": "Trump Says He’ll Set 50% Copper Tariff, Wait Year on Drug Levies",
    "summary": "(Bloomberg) -- President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200% tariff on their foreign-made products.Most Read from BloombergAre Tourists Ruining Europe? How Locals Are Pushing BackCan Americans Just Stop Building New Highways?Denver City Hall Takes a Page From NASAPhiladelphia Trash Piles Up as Garbage W",
    "url": "https://finnhub.io/api/news?id=1fccd845f4c89020e26d492afff3027881ba9c88390597dc1d1652f6a7556f03",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751998713,
      "headline": "Trump Says He’ll Set 50% Copper Tariff, Wait Year on Drug Levies",
      "id": 135818910,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- President Donald Trump said he planned to implement a 50% duty on copper imports as part of a set of looming sectoral tariffs, while also indicating he could offer pharmaceutical manufacturers at least a year before applying a crippling 200% tariff on their foreign-made products.Most Read from BloombergAre Tourists Ruining Europe? How Locals Are Pushing BackCan Americans Just Stop Building New Highways?Denver City Hall Takes a Page From NASAPhiladelphia Trash Piles Up as Garbage W",
      "url": "https://finnhub.io/api/news?id=1fccd845f4c89020e26d492afff3027881ba9c88390597dc1d1652f6a7556f03"
    }
  },
  {
    "ts": null,
    "headline": "Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali",
    "summary": "Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ongoing project developments and regulatory updates, such as the FDA's acceptance of a supplemental Biologics License Application for WINREVAIR, might have bolstered investor sentiment. Over the last quarter, Merck's share price increased by 2.47%. During this period, broader market movements,...",
    "url": "https://finnhub.io/api/news?id=9ba9ccb74f7be275b22e2133e1203b1ae10ba9b89352699b46d18ee65ec93a40",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751995927,
      "headline": "Merck (NYSE:MRK) To Present Promising HIV Research Data At IAS 2025 In Kigali",
      "id": 135811704,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ongoing project developments and regulatory updates, such as the FDA's acceptance of a supplemental Biologics License Application for WINREVAIR, might have bolstered investor sentiment. Over the last quarter, Merck's share price increased by 2.47%. During this period, broader market movements,...",
      "url": "https://finnhub.io/api/news?id=9ba9ccb74f7be275b22e2133e1203b1ae10ba9b89352699b46d18ee65ec93a40"
    }
  },
  {
    "ts": null,
    "headline": "AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?",
    "summary": "AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?",
    "url": "https://finnhub.io/api/news?id=4a4d2e484a5783d48b9c3ae552230dc702f6db466a214e2a91302d00d3ef90c3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751985780,
      "headline": "AstraZeneca Boasts Strong Oncology Portfolio: Can It Sustain Growth?",
      "id": 135811706,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "AZN's oncology sales rise 13% in Q1 2025, driven by key drugs and new approvals. Can this momentum last?",
      "url": "https://finnhub.io/api/news?id=4a4d2e484a5783d48b9c3ae552230dc702f6db466a214e2a91302d00d3ef90c3"
    }
  },
  {
    "ts": null,
    "headline": "Equine Healthcare Market Research and Forecast Report 2025-2034 | Top Players Drive Innovations, Strategic Collaborations and Product Expansion on the Rise",
    "summary": "The Global Equine Healthcare Market is poised for robust growth, valued at USD 2.5 billion in 2024 and projected to reach USD 4.6 billion by 2034, growing at a CAGR of 6.3%. The surge in market growth is driven by increased spending on equine health, preventive care adoption, and a rise in musculoskeletal and infectious diseases among horses. Key advancements include regenerative medicines, targeted therapies, and digital health tools. The pharmaceuticals segment, dominating with USD 817.9 milli",
    "url": "https://finnhub.io/api/news?id=284a4cd4f803996f3b6541c882388a83e1355db28a4469a3686a48dfcaf575d6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751984700,
      "headline": "Equine Healthcare Market Research and Forecast Report 2025-2034 | Top Players Drive Innovations, Strategic Collaborations and Product Expansion on the Rise",
      "id": 135806025,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "The Global Equine Healthcare Market is poised for robust growth, valued at USD 2.5 billion in 2024 and projected to reach USD 4.6 billion by 2034, growing at a CAGR of 6.3%. The surge in market growth is driven by increased spending on equine health, preventive care adoption, and a rise in musculoskeletal and infectious diseases among horses. Key advancements include regenerative medicines, targeted therapies, and digital health tools. The pharmaceuticals segment, dominating with USD 817.9 milli",
      "url": "https://finnhub.io/api/news?id=284a4cd4f803996f3b6541c882388a83e1355db28a4469a3686a48dfcaf575d6"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?",
    "summary": "GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.",
    "url": "https://finnhub.io/api/news?id=f8b2c22675443a40b2ae4cbfbb0f902ec696cfb15c05b2f5ba5439289ff5cf0f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751982660,
      "headline": "Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?",
      "id": 135809832,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.",
      "url": "https://finnhub.io/api/news?id=f8b2c22675443a40b2ae4cbfbb0f902ec696cfb15c05b2f5ba5439289ff5cf0f"
    }
  },
  {
    "ts": null,
    "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
    "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751981508,
      "headline": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "id": 135854926,
      "image": "",
      "related": "MRK",
      "source": "MarketWatch",
      "summary": "Trump says pharma tariffs may reach 200%, hitting in 12 to 18 months",
      "url": "https://finnhub.io/api/news?id=3077807c43b78e2edb81b8f062b911184ce713eb3b6e888f3ad03d1dd34750d6"
    }
  },
  {
    "ts": null,
    "headline": "Impactivize: Shareholders of 30 Companies Worth $13 Trillion Vote Overwhelmingly to Defeat Anti-DEI Proposals",
    "summary": "Shareholders of 30 major corporations, collectively valued at more than $13 trillion, have voted overwhelmingly to reject anti-DEI proposals during 2025 proxy season, delivering a resounding defeat to conservative activist groups seeking to eliminate diversity, equity and inclusion initiatives.",
    "url": "https://finnhub.io/api/news?id=4e0a7ed2b6b7a6002824a1ec7617d20d91ae7cf4035564165eb17ae940cefaa4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751979600,
      "headline": "Impactivize: Shareholders of 30 Companies Worth $13 Trillion Vote Overwhelmingly to Defeat Anti-DEI Proposals",
      "id": 135805512,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Shareholders of 30 major corporations, collectively valued at more than $13 trillion, have voted overwhelmingly to reject anti-DEI proposals during 2025 proxy season, delivering a resounding defeat to conservative activist groups seeking to eliminate diversity, equity and inclusion initiatives.",
      "url": "https://finnhub.io/api/news?id=4e0a7ed2b6b7a6002824a1ec7617d20d91ae7cf4035564165eb17ae940cefaa4"
    }
  },
  {
    "ts": null,
    "headline": "Certara Announces Expansion of Clinical Technology Collaboration with Merck",
    "summary": "Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management",
    "url": "https://finnhub.io/api/news?id=cae7c166600a25ce87159d584fca3b081e9a9f2d9157f6d5fe265ed567b75bf0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751976000,
      "headline": "Certara Announces Expansion of Clinical Technology Collaboration with Merck",
      "id": 135806028,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Expands use of the Certara Pinnacle 21® (P21) enterprise software platform to optimize clinical data flows for speed and qualityRADNOR, Pa., July 08, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced a new collaboration with Merck, known as MSD outside of the United States and Canada, that expands Merck’s use of the Certara Pinnacle 21 software platform to include a metadata repository and data standards workflow management",
      "url": "https://finnhub.io/api/news?id=cae7c166600a25ce87159d584fca3b081e9a9f2d9157f6d5fe265ed567b75bf0"
    }
  },
  {
    "ts": null,
    "headline": "Why SCHD Deserves The Benefit Of The Doubt",
    "summary": "SCHD offers a compelling blend of 3% yield, long-term dividend growth, and broad diversification for income-focused investors.",
    "url": "https://finnhub.io/api/news?id=97309fc4e3d3fe932c73b9b848a9e32a574af6ed8744e457ddccfcc651369a3a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751974387,
      "headline": "Why SCHD Deserves The Benefit Of The Doubt",
      "id": 135808154,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2190476050/image_2190476050.jpg?io=getty-c-w1536",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "SCHD offers a compelling blend of 3% yield, long-term dividend growth, and broad diversification for income-focused investors.",
      "url": "https://finnhub.io/api/news?id=97309fc4e3d3fe932c73b9b848a9e32a574af6ed8744e457ddccfcc651369a3a"
    }
  },
  {
    "ts": null,
    "headline": "Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025",
    "summary": "RAHWAY, N.J., July 08, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda.",
    "url": "https://finnhub.io/api/news?id=2f11b73d633e991013467e9342e730216086e1679e35c16ab51b2e65c5b0e596",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751971500,
      "headline": "Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025",
      "id": 135806029,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "RAHWAY, N.J., July 08, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) taking place July 13-17, 2025, in Kigali, Rwanda.",
      "url": "https://finnhub.io/api/news?id=2f11b73d633e991013467e9342e730216086e1679e35c16ab51b2e65c5b0e596"
    }
  },
  {
    "ts": null,
    "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
    "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
    "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1751969010,
      "headline": "Analysis: 'Trump Effect' website takes credit for US investment made under Biden",
      "id": 135804198,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Since then, Trump has said the investments have swelled to $14 trillion, or roughly half of the nation's annual gross domestic product.  The White House calls it \"The Trump Effect\" and features a rolling list on its website of more than 70 projects it says Trump's economic policies spurred, from a new bakery plant in Texas to a LEGO facility in Virginia and a microchip plant in Arizona.",
      "url": "https://finnhub.io/api/news?id=92e2dc58d493ce2276eb1aaea4aa576578a366cd8c115d7728a13b84fa6525b0"
    }
  }
]